So the two key questions in protease-based drug discovery are: how specific should an inhibitor be to deliver a therapeutic outcome and what are the best ways to achieve the specificity needed?

HIV-1 protease is a crucial enzyme in the life cycle of the Human Immunodeficiency Virus (HIV), and it has been a primary target for antiretroviral therapy. However, the emergence of drug ...

Generally, drugs from two (or sometimes three) classes are combined to ensure a combined attack on HIV. The four main classes, which most people are treated with, target one of three viral proteins ...

The proof-of-concept demonstrates the power of pairing AI with lab orchestration solutions to automate molecular screening ...

but the Phase III SCORPIO-HR trial studying the drug failed to meet its primary endpoint. However, subsequent data suggested that Xocova reduced symptomatic infections in household settings when ...

While there are already drugs to inhibit the SARS-CoV-2 main protease, utilizing natural substances may lead to the development of safer treatments. As various virus strains have a common main ...

protease drug IdeXork (Xork) alongside Astellas' AT845, currently in the phase 1/2 FORTIS study in late-onset Pompe disease (LOPD) in adults. Xork is designed as a pre-treatment to overcome one of ...

Traws Pharma has completed the Phase I clinical trials of tivoxavir marboxil, a single-dose drug for treating or preventing H5N1 bird flu. The randomised, placebo-controlled, double-blind trial ...

Transmitted drug resistance (TDR ... of resistant viral strains from treated to untreated individuals. TDR to protease inhibitors, nucleoside reverse-transcriptase inhibitors and non-nucleoside ...

Transmitted drug resistance (TDR ... of resistant viral strains from treated to untreated individuals. TDR to protease inhibitors, nucleoside reverse-transcriptase inhibitors and non-nucleoside ...

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Cocrystal Pharma (COCP – Research Report) today and set a price target of ...